Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Lymphoid 2Dermatologic 1

Conditions

Mycosis Fungoides 2Neoplasms 1Lymphoma, T-Cell, Cutaneous 1

Interventions

hypericin 4zanolimumab 3mogamulizumab 3cobomarsen 3Vorinostat 3Bexarotene 3denileukin diftitox 2Vitamin B 12 2Panobinostat 2Folic Acid 2Amines 2A-dmDT390-bisFv(UCHT1) protein 210-propargyl-10-deazaaminopterin 2talimogene laherparepvec 1resminostat 1ontuxizumab 1navitoclax 1forodesine 1TTI-621 1Radiation 1N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide 1Methotrexate 1Mechlorethamine 1MAC-ST-001 1Interleukin-12 Subunit p35 1Fentanyl 1Fenretinide 1Duration of Therapy 1Drug Therapy 1Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Mycosis Fungoides × Amines × Clear all
NCT06149247 2025-08-20

HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL

Soligenix

Phase 2 Completed
10 enrolled 7 charts
Lymphoid

Mycosis Fungoides

NCT02296164 2020-03-04

PROVe

Helsinn Therapeutics (U.S.), Inc

Completed
300 enrolled 7 charts
DermatologicLymphoid

Mycosis Fungoides, Neoplasms, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡